![]() |
|
|
Vol. 294, Issue 3, 830-836, September 2000
-Glucoside across
Human Intestinal Caco-2 Cell Monolayers by Apical Multidrug
Resistance-Associated Protein-21
Department of Cell and Molecular Pharmacology and Experimental Therapeutics (R.A.W., G.E.L., T.W.) and Department of Cell Biology and Anatomy (K.J.K.), Medical University of South Carolina, Charleston, South Carolina
| |
Abstract |
|---|
|
|
|---|
Although there is strong evidence to suggest that flavonoid consumption
is beneficial to human health, the extent to which flavonoids are
absorbed and the mechanisms involved are controversial. Contrary to
common dogma, we previously demonstrated that quercetin 4'-
-glucoside, the predominant form of the most abundant dietary flavonoid, quercetin, was not absorbed across Caco-2 cell monolayers. The aim of this study was to test the hypothesis that a specific efflux
transporter is responsible for this lack of absorption. Transport of
quercetin 4'-
-glucoside, alone or with inhibitors, was examined with
Caco-2 cell monolayers. In addition, subcellular localization of the
multidrug resistance-associated proteins MRP1 and MRP2 was examined by
immunofluorescent confocal microscopy. Efflux of quercetin
4'-
-glucoside, a saturable process, was not altered by verapamil, a
P-glycoprotein inhibitor, but was competitively inhibited by MK-571, an
MRP inhibitor. These data in combination with immunofluorescent
localization of MRP2 to the apical membrane support a role for MRP2 in
the intestinal transcellular efflux of quercetin 4'-
-glucoside.
These results suggest a role for MRP2 in the transport of a new class
of agents, dietary glucosides.
| |
Introduction |
|---|
|
|
|---|
Flavonoids
are highly diverse, low molecular weight polyphenolic compounds. Due to
their ubiquitous distribution in plants, humans are constantly exposed
to a large variety of flavonoids, but precise exposure levels are not
yet known. Although early estimates reported the average intake of all
flavonoids to be as high as 1 g/day (Pierpoint, 1986
), newer data
suggest that the daily intake may be lower. Based on data from The
Netherlands, a Western diet contains approximately 16 mg/day of the
most commonly consumed flavonoid, quercetin (Hertog et al., 1993
).
However, very large interindividual variability can be expected based
on dietary preferences. Significant sources of quercetin include onions, apples, tea, and red wines.
Epidemiological data have demonstrated an association between a diet
that is rich in quercetin and a significant reduction in the risk of
mortality from coronary heart disease (Hertog et al., 1993
; Knekt et
al., 1996
) and a reduced risk of stroke (Keli et al., 1996
). Quercetin
is a potent antioxidant, which chelates metal ions to prevent the
Fenton reaction and is capable of scavenging hydroxyl and peroxy
radicals (Manach et al., 1996
). In addition, quercetin and quercetin
monoglucosides have been shown to inhibit 15-lipoxygenase, an enzyme
thought to play a role in the oxidative modification of low density
lipoprotein, leading to foam cell formation in the early
development of atherosclerosis (da Silva et al., 1998
).
Epidemiological studies also support an association between dietary
flavonoids and a reduced risk of certain cancers, including stomach
carcinoma and lung cancer (Dorant et al., 1996
; Knekt et al., 1997
).
Animal studies (Deschner et al., 1993
) as well as in vitro studies
suggest that the flavonoids exert preventive effects in cancer.
Proposed mechanisms for anticancer benefits include numerous effects on
signal transduction pathways involved in cell proliferation (Weber et
al., 1996
; Lepley and Pelling, 1997
) and angiogenesis (Fotsis et al.,
1997
), as well as inhibition of enzymes involved with procarcinogen
bioactivation such as cytochrome P450 (Tsyrlov et al., 1994
) and
sulfotransferase enzymes (Walle et al., 1995
).
Although there is strong evidence to suggest beneficial effects of
flavonoids in human health, the extent and mechanism by which
flavonoids reach the systemic circulation from dietary sources are
controversial. Plant flavonoids are predominantly found as
-glycosides with flavonols (including quercetin) existing as 3, 7, and 4' O-glycosides, whereas other flavonoids, such as
flavones, flavonones, and isoflavones, are mainly glycosylated at
position 7 (Price et al., 1997
; Fossen et al., 1998
). With the notable exception of fermentation and autolysis, which release the aglycone, flavonoid glycosides are relatively resistant to most food preparation methods (Coward et al., 1993
). Thus, when consumed, flavonoids are
present primarily as glycosides.
An original model of flavonoid bioavailability assumed that flavonoid
glycosides were too polar to be absorbed from the small intestine and
that absorption was dependent on the cleavage of the
-glycoside
linkage by the colonic microflora (Griffiths and Barrow, 1972
). Hollman
et al. (1995)
indirectly calculated the absorption of quercetin
aglycone as well as quercetin glucosides from an onion meal in
ileostomy patients. Based on the results, they proposed that quercetin
glucosides were actively absorbed via the intestinal glucose
transporter. In a direct examination of the transcellular absorption of
quercetin glucosides with the Caco-2 cell model of human intestinal
absorption, in which glucose is very rapidly absorbed, we found that
quercetin 4'-
-glucoside was not absorbed, whereas quercetin
3,4'-
-diglucoside demonstrated minimal absorption (Walgren et al.,
1998
). In fact, contrary to all hypotheses, both of these glucosides
demonstrated significant efflux, suggesting that a drug efflux pump may
be involved in the basolateral-to-apical transport of these dietary components.
In this study, we have examined the role of known intestinal efflux
pumps in the transcellular efflux of quercetin 4'-
-glucoside in
human intestinal Caco-2 cell monolayers. Our observations indicate that
the multidrug resistance-associated protein MRP2 plays a major role in
this efflux. MRP2 identification and subcellular localization to the
apical membrane in the Caco-2 cells were established by
immunofluorescent confocal microscopy.
| |
Materials and Methods |
|---|
|
|
|---|
MK-571 was a generous gift from A. W. Ford-Hutchinson,
Merck-Frosst Center for Therapeutic Research, Pointe Claire-Dorval, Quebec, Canada. Dulbecco's PBS with 0.1 g
l
1 calcium chloride was purchased from Life
Technologies (Grand Island, NY). Quercetin 4'-
-glucoside was
isolated from the red onion as described previously (Walgren et al.,
1998
). Verapamil HCl was obtained from Knoll Pharmaceutical (Whippany,
NJ). Anti-human MRP1 and MRP2 antibodies were purchased from Kamiya
Biomedical (Seattle, WA). Except where noted, all other chemicals were
purchased from Sigma Chemical Co. (St. Louis, MO).
Cell Culture.
Caco-2 cells obtained from American Type
Culture Collection (Rockville, MD) were cultured in Eagle's minimum
essential medium (MEM) (Cellgro; Mediatech, Herndon, VA) supplemented
with 1% MEM nonessential amino acids (Mediatech), 10% fetal bovine
serum (Summit Biotechnology, Fort Collins, CO), 100 U
ml
1 penicillin, and 0.1 mg
ml
1 streptomycin and were grown in a humidified
atmosphere of 5% CO2 at 37°C. Cells were
subcultured at 80% confluence.
Transport Studies.
For all transcellular transport studies,
Caco-2 cells were seeded in 12-mm i.d. Transwell inserts (polycarbonate
membrane, 0.4-µm pore size; Corning Costar Corp., Cambridge, MA) in
12-well plates at a density of 1.0 × 105
cells cm
2. The basolateral (serosal) and apical
(mucosal) compartments contained 1.5 and 0.5 ml of culture medium,
respectively. Culture medium was replaced three times a week for 14 days and daily thereafter. Caco-2 cells in Transwells at passage 48 to
93 were used for transport experiments 18 to 25 days post seeding.
Inserts with transepithelial electrical resistance (TEER) values >350
cm2 in culture medium were washed twice for
30 min with warm PBS.
-glucoside in ethanol were diluted
with PBS before transport experiments. The resulting maximum final
concentration of ethanol, 0.5%, did not affect TEER values or the
transport of mannitol, a marker of paracellular transport. All other
compounds were dissolved in transport medium. Transport medium
containing substrate was added to either the apical (0.5 ml) or
basolateral (1.5 ml) side of the inserts, whereas the receiving chamber
contained the corresponding volume of PBS. Where applicable, inhibitors
(MK-571, verapamil) were added to both chambers. Upon termination of
the 1-h incubation at 37°C, samples were collected for immediate analysis.
Samples containing quercetin 4'-
-glucoside were quantified by
reversed phase HPLC on a Millennium HPLC system (Waters Corp., Milford,
MA) with a Symmetry C18 column, 3.9 × 150 mm, and a model 996 photodiode array detector. The mobile phase consisted of 35% methanol
in 5% acetic acid with a flow rate of 0.9 ml
min
1. Quercetin 4'-
-glucoside peak areas
were measured at 370 nm.
Calculations and Statistics.
Apparent permeability
coefficients (Papp) were calculated with
the following equation:
|
Immunofluorescent Localization of MRP in Caco-2 Cells. Washed confluent monolayers of Caco-2 cells grown on Transwells were fixed at room temperature with 3% paraformaldehyde for 15 min to preserve three-dimensional structure. Cells were then permeabilized for 10 min with 0.1% Triton X-100 and blocked for 30 min with 5% normal goat serum. Inserts were incubated for 1 h with antibodies raised against MRP2 (M2I-4, M2III-6) or MRP1 (MRPr1, MRPm6). Primary antibody binding was detected with Alexa 488 goat anti-mouse IgG (MRPm6, M2I-4, M2III-6) or fluorescein isothiocyanate anti-rat IgG (MRPr1; Molecular Probes, Eugene, OR). Cells were incubated for 3 min with propidium iodide for counterstaining of nucleic acids. Alternately, fixed Caco-2 monolayers on polycarbonate membranes were cut from Transwells, embedded in O.C.T. Compound (Miles, Elkhart, IN) and frozen with liquid nitrogen. Frozen sections (5 µm) were cut perpendicular to the membrane. Sections were then permeabilized and stained as described above. Stained monolayers and sections were examined with a Bio-Rad MRC 1024 laser scanning confocal microscope (Hercules, CA). To control for nonspecific binding, matching inserts were treated similarly but with the omission of the primary antibody.
| |
Results |
|---|
|
|
|---|
Transcellular Efflux of Quercetin 4'-
-Glucoside.
Efflux of
quercetin 4'-
-glucoside was monitored by a molecularly specific HPLC
method at 370 nm as depicted in Fig. 1.
Formation of quercetin or quercetin glucuronides was not observed. The
latter was a distinct possibility based on a previous study in the rat intestine (Crespy et al., 1999
). However, formation of the glucuronides was ruled out based on the absence of peaks at the retention times (5.0, 6.0, and 10.3 min) identified for the three glucuronides formed
when quercetin was incubated with human liver microsomes or recombinant
human UGT1A9 and the cofactor UDP-glucuronic acid (Y. Otake and T. Walle, unpublished data).
|
-glucoside across Caco-2 cell monolayers
was examined for concentration dependence. Transport of quercetin
4'-
-glucoside was determined in the basolateral-to-apical direction
over the concentration range of 10 to 300 µM (Fig.
2A). The apparent permeability
coefficient decreased significantly with increased concentration over
the range examined, from 3.87 ± 0.40 × 10
6 cm s
1 at 10 µM to
0.75 ± 0.06 × 10
6 cm
s
1 at 300 µM, consistent with a saturable
secretory mechanism. The solubility of quercetin 4'-
-glucoside was
determined to be >300 µM and, thus, did not influence the results
shown in Fig. 2A.
|
-glucoside, we examined the
role of P-glycoprotein and the MRPs by measuring efflux in the presence
of selective inhibitors (Fig. 2B). Verapamil, an inhibitor of
P-glycoprotein, did not significantly alter the flux of quercetin
4'-
-glucoside in the basolateral-to-apical direction,
Papp of 2.36 ± 0.09 × 10
6 cm s
1 in control
inserts versus 2.04 ± 0.23 × 10
6 cm
s
1 with 50 µM verapamil. The presence of 50 µM MK-571, an MRP inhibitor, resulted in a greater than 80%
reduction in apparent permeability, 0.40 ± 0.04 × 10
6 cm s
1
(P < .001). This finding in combination with the
previous detection in our laboratory of MRP2 but not MRP1 in Caco-2
cells (Walle et al., 1999b
-glucoside.
Kinetic Properties of Quercetin 4'-
-Glucoside
Efflux
To examine the mechanism of inhibition and
determine apparent kinetic constants, we examined quercetin
4'-
-glucoside efflux over a range of substrate and MK-571
concentrations, 10 to 300 µM and 0.1 to 50 µM, respectively. Data
were acquired in three separate experiments each with triplicate
determinations at each substrate and inhibitor concentration. Both
transport of quercetin 4'-
-glucoside and inhibition of transport by
MK-571 demonstrated concentration dependence (Fig.
3). Data were fitted to one- and two-component models of competitive, noncompetitive, and uncompetitive inhibition with the Solver function in Microsoft Excel 97. Results obtained with a two-component model were not different from those obtained with a one-component model, and the simpler model was adopted.
The best fit was obtained with a one-component model of competitive
inhibition. Data are summarized in Table
1.
|
|
Transcellular Absorption of Quercetin
4'-
-Glucoside
In our previous studies, we have
demonstrated a lack of apical to basolateral absorption of quercetin
4'-
-glucoside across Caco-2 monolayers. Efflux of the monoglucoside
across the apical membrane by MRP2 is one potential explanation for
this observation. To test this possibility we examined the
apical-to-basolateral flux of quercetin 4'-
-glucoside in the
presence of 50 µM MK-571. Transport of quercetin 4'-
-glucoside was
not observed at substrate concentrations less than 250 µM. A modest
but statistically significant (P < .001)
absorption, Papp = 0.032 ± 0.008 × 10
6 cm s
1, was observed at
250 µM quercetin 4'-
-glucoside in the presence of 50 µM MK-571.
No absorption was detected in the presence of 50 µM verapamil.
Immunofluorescent Localization of MRP2 in Caco-2 Cell
Monolayers.
The subcellular distribution of MRP isoforms was
visualized in confluent Caco-2 cell monolayers grown on Transwells by
indirect immunofluorescent localization with a laser scanning confocal microscope. Cells were seeded onto polycarbonate inserts and grown under conditions identical to those used to grow cells for transport studies and monolayer integrity was determined by TEER. Consistent with
our previous data from Western blot analysis (Walle et al., 1999b
), monolayers stained with the anti-MRP1 antibody MRPm6
were void of green signal and appeared similar to control samples where primary antibodies were omitted (Fig. 4,
A and B). Identical results were obtained with MRPr1 (data not shown).
In contrast, samples stained with the anti-MRP2 antibody
M2III-6 demonstrated significant green signal
(Fig. 4C) and similar results were observed with M2I-4 (data not shown). Optical sectioning of the
z-series perpendicular to the plane of the cell monolayer
demonstrated that the subcellular localization of MRP2 was restricted
to the apical side of the cells (Fig. 4C, bottom), whereas no evidence
for MRP1 was observed (Fig. 4B, bottom). To enhance resolution and
verify the apical staining of MRP2, we examined MRP2 localization in
5-µm sections cut perpendicular to the plane of the cell monolayer.
Sections stained with M2III-6 showed that MRP2
immunostaining was primarily confined to the apical plasma membrane,
with some diffuse intracellular staining (Fig. 4D).
|
| |
Discussion |
|---|
|
|
|---|
A large body of evidence supports a beneficial role for flavonoids
in human health. Although the flavonoid content in the human diet is
significant, dietary forms of quercetin have demonstrated very poor and
variable absorption in rats and humans (Gugler et al., 1975
; Ueno et
al., 1983
; Hollman et al., 1997
; Manach et al., 1997
). To understand
the mechanisms governing the intestinal absorption of flavonoids we
have examined transport of quercetin 4'-
-glucoside with human Caco-2
cell monolayers, an accepted model of the human intestinal epithelium.
Previously, we have shown that although quercetin 4'-
-glucoside is
not absorbed across this intestinal epithelium, it is effluxed (Walgren
et al., 1998
). This unidirectional flux suggested the possibility that
an efflux pump was involved, and in this study, we have presented
evidence to support this hypothesis. First, the transport of quercetin 4'-
-glucoside in the basolateral-to-apical direction demonstrated saturation over the concentration range of 10 to 300 µM, consistent with a saturable secretory mechanism. Second, the efflux of quercetin 4'-
-glucoside was competitively inhibited by MK-571, a selective inhibitor of the closely related MRP1 and MRP2 isoforms (Jedlitschky et
al., 1994
; Leier et al., 1994
; Büchler et al., 1996
). This observation in combination with the identification of MRP2 but not MRP1
in our Caco-2 cell monolayers supports a role for MRP2 in the efflux of
quercetin 4'-
-glucoside across the apical membranes of enterocytes.
Although MRP1 was originally associated with chemotherapeutic
resistance, MRP isoforms have since been found to be constitutively expressed in a number of tissues. Within the human intestine, Northern
blot analysis demonstrates expression of the message for MRP1, MRP2,
MRP3, and MRP5 (Kool et al., 1997
). Although the spectrum of substrates
is similar or identical for MRP1 and MRP2 (Jedlitschky et al., 1994
;
Leier et al., 1994
; Müller et al., 1994
), the cellular
localization of these two proteins is different. In hepatocytes, MRP1
is present in lateral membranes, whereas MRP2 is restricted to apical
canalicular membranes (Büchler et al., 1996
; Roelofsen et al.,
1999
). Similar to MRP1, MRP3 appears to be expressed in the basolateral
membrane of human hepatocytes (König et al., 1999
). Currently,
little is known about the transport characteristics and cellular
localization of MRP5.
Although the cellular localization of the MRP isoforms has been
determined within the liver, their localization within the gastrointestinal tract is uncertain. Flens et al. (1996)
have previously examined MRP1 expression by immunohistochemistry in normal
human tissues. Within the small intestine, epithelial cells demonstrated a supranuclear cytoplasmic staining, but the brush border
and goblet cells were negative. Despite a recent claim that Caco-2
cells express MRP1 (Gutmann et al., 1999
), previous efforts in our
laboratory with Western blot analysis have demonstrated the presence of
MRP2 but not MRP1 in Caco-2 cells (Walle et al., 1999b
). This apparent
discrepancy may result from differences in culture conditions because
age and seeding density have been shown to influence expression of MRP1
and MRP2 in cultured hepatocytes (Roelofsen et al., 1999
). In this
study, we have examined confluent Caco-2 cell monolayers for expression
of MRP1 and MRP2 by indirect immunofluorescent localization with laser
scanning confocal microscopy. Monolayers were grown in Transwells under
identical conditions to those used to grow cells for our transport
studies. In agreement with our previous finding, we observed expression
of MRP2 but not MRP1. The immunostaining of MRP2 was primarily confined
to the apical plasma membrane. This pattern of distribution is
consistent with the distribution observed in polarized hepatocytes and
similar to that observed in MRP2-transfected Madin-Darby canine kidney cell monolayers (Evers et al., 1998
). An apical localization of MRP2
within the intestine would place this transporter in a position to both
protect against the absorption of compounds from the lumen and secrete
agents into the lumen for removal from the body.
Our kinetic studies with intact cell monolayers revealed that the
efflux of quercetin 4'-
-glucoside was competitively inhibited by
MK-571 with an apparent KI of 5.6 µM. This value is similar to values observed by Paul et al. (1996)
with membrane vesicles from NIH 3T3 cells transfected with MRP1
(KI = 2.5 µM) but less potent than
values reported by Jedlitschky et al. (1994)
who used membrane vesicles
from MRP1-transfected HeLa cells (KI = 0.7 µM). Although comparable values from MRP2 membrane vesicles are
not available, it has previously been reported that MK-571 is a
slightly less potent inhibitor of MRP2 (Büchler et al., 1996
).
Inhibition of quercetin 4'-
-glucoside efflux by MK-571 in
combination with the identification of MRP2 expression in the apical membranes of Caco-2 cell monolayers strongly implicates a role for MRP2
in the transcellular efflux of this glucoside. The apparent affinity of
quercetin 4'-
-glucoside for MRP2
(Km = 43.6 ± 7.4 µM) does not
place this agent among the highest affinity substrates for this
transporter. However, the apparent affinity does lie within the
predicted lumenal concentration of quercetin 4'-
-glucoside after
consumption of a single meal in a typical Western diet (Walgren et al.,
1998
). This is significant because it allows transport to increase in
proportion to increased consumption. A transporter with a lower
Km would already be functioning close
to the Vmax and would therefore be
unable to compensate for such an increase in concentration.
The spectrum of agents recognized as substrates by MRP1 and MPR2 is
similar, consisting primarily of organic anions, and is principally
composed of glutathione and glucuronic acid conjugates of lipophilic
compounds (König et al., 1999
). It is therefore surprising that
quercetin 4'-
-glucoside, an uncharged molecule, is a substrate for
MRP2. Previously, in a preliminary study, we have shown evidence that
another glucoside, genistin, is a substrate for MRP2 (Walle et al.,
1999a
). The finding that genistin and quercetin 4'-
-glucoside are
both substrates for MRP2 suggests that a large new class of agents may
be substrates for MRP-mediated transport.
In agreement with the hypothesis that MRP2 is limiting transcellular
absorption of quercetin 4'-
-glucoside we have previously demonstrated a lack of apical-to-basolateral absorption of this agent
across Caco-2 monolayers (Walgren et al., 1998
). To further test this
hypothesis we have examined the transcellular absorption of quercetin
4'-
-glucoside, at various substrate concentrations, in the presence
of 50 µM MK-571. In contrast to control treatments that did not
demonstrate absorption at any substrate concentration, a modest
absorption was observed at 250 µM quercetin 4'-
-glucoside in the
presence of 50 µM MK-571, supporting this hypothesis but also
suggesting that an additional transport mechanism may be involved,
preventing quercetin 4'-
-glucoside from crossing the basolateral
membrane. Toxicity of MK-571 at higher concentrations and a limited
solubility range for quercetin 4'-
-glucoside have limited further
testing (data not shown).
In summary, this study demonstrates that MRP2 is localized to the
apical membrane of Caco-2 cells and that this protein both limits the
absorption of and mediates the efflux of quercetin 4'-
-glucoside
across Caco-2 cell monolayers.
| |
Acknowledgment |
|---|
We thank Martina Sedmerova for assistance with the immunofluorescent localization of MRP in Caco-2 cells.
| |
Footnotes |
|---|
Accepted for publication May 5, 2000.
Received for publication March 6, 2000.
1 This study was supported by National Institutes of Health Grant GM55561 and Department of Defense, Army Breast Cancer Program Grant DAMD17-98-1-8125.
Send reprint requests to: Thomas Walle, Ph.D., Medical University of South Carolina, Department of Cell and Molecular Pharmacology and Experimental Therapeutics, 173 Ashley Ave., P.O. Box 250505, Charleston, SC 29425. E-mail: wallet{at}musc.edu
| |
Abbreviations |
|---|
MRP, multidrug resistance-associated protein; MEM, minimum essential medium; TEER, transepithelial electrical resistance.
| |
References |
|---|
|
|
|---|
-glycoside conjugates: Antitumor isoflavones in soybean foods from American and Asian diets.
J Agric Food Chem
41:
1961-1967.This article has been cited by other articles:
![]() |
G. Williamson, I. Aeberli, L. Miguet, Z. Zhang, M.-B. Sanchez, V. Crespy, D. Barron, P. Needs, P. A. Kroon, H. Glavinas, et al. Interaction of Positional Isomers of Quercetin Glucuronides with the Transporter ABCC2 (cMOAT, MRP2) Drug Metab. Dispos., August 1, 2007; 35(8): 1262 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Choudhuri and C. D. Klaassen Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters International Journal of Toxicology, July 1, 2006; 25(4): 231 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, M. Huang, S. Guan, H.-C. Bi, Y. Pan, W. Duan, S. Y. Chan, X. Chen, Y.-H. Hong, J.-S. Bian, et al. A Mechanistic Study of the Intestinal Absorption of Cryptotanshinone, the Major Active Constituent of Salvia miltiorrhiza J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1285 - 1294. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Graf, W. Mullen, S. T. Caldwell, R. C. Hartley, G. G. Duthie, M. E. J. Lean, A. Crozier, and C. A. Edwards DISPOSITION AND METABOLISM OF [2-14C]QUERCETIN-4'-GLUCOSIDE IN RATS Drug Metab. Dispos., July 1, 2005; 33(7): 1036 - 1043. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. A. Sesink, I. C. W. Arts, V. C. J. de Boer, P. Breedveld, J. H. M. Schellens, P. C. H. Hollman, and F. G. M. Russel Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Net Intestinal Uptake of Quercetin in Rats by Facilitating Apical Efflux of Glucuronides Mol. Pharmacol., June 1, 2005; 67(6): 1999 - 2006. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Walle, A. M. Browning, L. L. Steed, S. G. Reed, and U. K. Walle Flavonoid Glucosides Are Hydrolyzed and Thus Activated in the Oral Cavity in Humans J. Nutr., January 1, 2005; 135(1): 48 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Prime-Chapman, R. A. Fearn, A. E. Cooper, V. Moore, and B. H. Hirst Differential Multidrug Resistance-Associated Protein 1 through 6 Isoform Expression and Function in Human Intestinal Epithelial Caco-2 Cells J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 476 - 484. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Imai, S. Tsukahara, S. Asada, and Y. Sugimoto Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance Cancer Res., June 15, 2004; 64(12): 4346 - 4352. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Siccardi, L. E. Kandalaft, M. Gumbleton, and C. McGuigan Stereoselective and Concentration-Dependent Polarized Epithelial Permeability of a Series of Phosphoramidate Triester Prodrugs of d4T: An in Vitro Study in Caco-2 and Madin-Darby Canine Kidney Cell Monolayers J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1112 - 1119. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Walle and U. K. Walle THE {beta}-D-GLUCOSIDE AND SODIUM-DEPENDENT GLUCOSE TRANSPORTER 1 (SGLT1)-INHIBITOR PHLORIDZIN IS TRANSPORTED BY BOTH SGLT1 AND MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS 1/2 Drug Metab. Dispos., November 1, 2003; 31(11): 1288 - 1291. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Vaidyanathan and T. Walle Cellular Uptake and Efflux of the Tea Flavonoid (-)Epicatechin-3-gallate in the Human Intestinal Cell Line Caco-2 J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 745 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. E. Spencer Metabolism of Tea Flavonoids in the Gastrointestinal Tract J. Nutr., October 1, 2003; 133(10): 3255S - 3261. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L Prior Fruits and vegetables in the prevention of cellular oxidative damage Am. J. Clinical Nutrition, September 1, 2003; 78(3): 570S - 578. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Petri, C. Tannergren, B. Holst, F. A. Mellon, Y. Bao, G. W. Plumb, J. Bacon, K. A. O'Leary, P. A. Kroon, L. Knutson, et al. ABSORPTION/METABOLISM OF SULFORAPHANE AND QUERCETIN, AND REGULATION OF PHASE II ENZYMES, IN HUMAN JEJUNUM IN VIVO Drug Metab. Dispos., June 1, 2003; 31(6): 805 - 813. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. A. Sesink, I. C. W. Arts, M. Faassen-Peters, and P. C.H. Hollman Intestinal Uptake of Quercetin-3-Glucoside in Rats Involves Hydrolysis by Lactase Phlorizin Hydrolase J. Nutr., March 1, 2003; 133(3): 773 - 776. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Setchell, N. M Brown, L. Zimmer-Nechemias, W. T Brashear, B. E Wolfe, A. S Kirschner, and J. E Heubi Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability Am. J. Clinical Nutrition, August 1, 2002; 76(2): 447 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu and M. Hu Absorption and Metabolism of Flavonoids in the Caco-2 Cell Culture Model and a Perused Rat Intestinal Model Drug Metab. Dispos., April 1, 2002; 30(4): 370 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wolffram, M. Block, and P. Ader Quercetin-3-Glucoside Is Transported by the Glucose Carrier SGLT1 across the Brush Border Membrane of Rat Small Intestine J. Nutr., April 1, 2002; 132(4): 630 - 635. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Rost, S. Mahner, Y. Sugiyama, and W. Stremmel Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine Am J Physiol Gastrointest Liver Physiol, April 1, 2002; 282(4): G720 - G726. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Wenzel, S. Kuntz, and H. Daniel Flavonoids with Epidermal Growth Factor-Receptor Tyrosine Kinase Inhibitory Activity Stimulate PEPT1-Mediated Cefixime Uptake into Human Intestinal Epithelial Cells J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 351 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Walle, U. K. Walle, and P. V. Halushka Carbon Dioxide Is the Major Metabolite of Quercetin in Humans J. Nutr., October 1, 2001; 131(10): 2648 - 2652. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. A. Sesink, K. A. O'Leary, and P. C. H. Hollman Quercetin Glucuronides but Not Glucosides Are Present in Human Plasma after Consumption of Quercetin-3-Glucoside or Quercetin-4'-Glucoside J. Nutr., July 1, 2001; 131(7): 1938 - 1941. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Donovan, V. Crespy, C. Manach, C. Morand, C. Besson, A. Scalbert, and C. Rémésy Catechin Is Metabolized by Both the Small Intestine and Liver of Rats J. Nutr., June 1, 2001; 131(6): 1753 - 1757. [Abstract] [Full Text] |
||||
![]() |
E. M. Leslie, Q. Mao, C. J. Oleschuk, R. G. Deeley, and S. P. C. Cole Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1) Transport and ATPase Activities by Interaction with Dietary Flavonoids Mol. Pharmacol., April 16, 2001; 59(5): 1171 - 1180. [Abstract] [Full Text] |
||||
![]() |
T. Walle, Y. Otake, U. K. Walle, and F. A. Wilson Quercetin Glucosides Are Completely Hydrolyzed in Ileostomy Patients before Absorption J. Nutr., November 1, 2000; 130(11): 2658 - 2661. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Walgren, J.-T. Lin, R. K.-H. Kinne, and T. Walle Cellular Uptake of Dietary Flavonoid Quercetin 4'-beta -Glucoside by Sodium-Dependent Glucose Transporter SGLT1 J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 837 - 843. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||